Indeed, inhibitors of myeloperoxidase are being developed as a treatment strategy for neutrophil-associated lung disease.52 Relevant here, though, is our finding that normalization of sputum EPX by mepolizumab did not result in normalization of lung function. Here, MPO is linked to lung disorder.